Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)

Trial ID or NCT#



not recruiting iconNOT RECRUITING


To assess whether changes in quantitative tumor perfusion parameters after 3 weeks of treatment, as measured by power Doppler ultrasound, can predict initial objective response, defined by current standard-of-care, to therapy at 12 weeks after start of treatment

Official Title

Early Therapeutic Monitoring of Response to Therapy With Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - 18 years of age or older - Pathology-confirmed diagnosis of metastatic RCC - At least one tumor lesion greater than 1 cm in diameter, amenable to ultrasound imaging - Written informed consent. Specific inclusion criteria: - arm 1: planned to be treated with combination of VEGFR2 tyrosine kinase inhibitor (TKI) plus immune checkpoint inhibitor (ICI) - arm 2: planned to be treated with non-ICI therapy
Exclusion Criteria:
  1. -Any comorbid condition that, in the opinion of the treating provider or the Protocol Directors, compromises the participant's ability to participate in the study


Alice C. Fan
Alice C. Fan
Medical oncologist, Genitourinary specialist
Associate Professor of Medicine (Oncology) and, by courtesy, of Urology
Jeremy Dahl
Aya Kamaya, MD
Aya Kamaya, MD
Professor of Radiology (Body Imaging)
Ali Raza Khaki, MD
Ali Raza Khaki, MD
Genitourinary specialist, Medical oncologist
Clinical Assistant Professor, Medicine - Oncology

Contact us to find out if this trial is right for you.


Christian Hoerner, PhD